This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Silodosin vs Placebo in the Treatment of Female LUTS

Sponsored by Mansoura University

About this trial

Last updated 2 years ago

Study ID

Silodosin for female LUTS

Status

Not yet recruiting

Type

Interventional

Phase

Phase 3

Placebo

Yes

Accepting

18-75 Years
21 to 75 Years
Female
Female

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 6 months ago

What is this trial about?

This trial will be conducted to study the efficacy and safety of Silodosin in the treatment of female lower urinary tract symptoms.

What are the participation requirements?

Yes

Inclusion Criteria

- Females complaining of lower urinary tract symptoms

- IPSS ≥ 8 or OAB - V8 score ≥ 8

No

Exclusion Criteria

1. Patients with documented hypersensitivity to Silodosin.

2. Patients receiving alpha blockers or anticholinergic medications for any other reason.

3. Patients with history of orthostatic hypotension.

4. Pregnant or breastfeeding females.

5. Patients with stress urinary incontinence.

6. Patients with active urinary tract infection.

7. History of previous pelvic surgery or radiation.

8. Patient with diabetes mellitus.

9. Patients diagnosed with bladder cancer.

10. Patients with hepatic impairment (Child-Pugh score >9).

11. Patients with severe renal impairment with creatinine clearance of less than 10 mL/min.

12. Patients planned to undergo any ophthalmic procedure.

13. Patients with history of urinary retention or gastric retention.